Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.47 |
| ▸ | PTGES | O14684 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SDCBP | O00560 | 1/20 | 0.41 |
| ▸ | SDC2 | P34741 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19501967 | 0.84 | HTT (0.72) | HTTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL1747654 | 0.84 | HTT (0.72) | HTTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL1931269 | 0.83 | HTT (0.71) | HTTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL9099120 | 0.83 | HTT (0.71) | HTTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL19501679 | 0.82 | HTT (1.00) | HTTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL14117471 | 0.82 | HTT (0.70) | HTTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL7393331 | 0.82 | HTT (0.70) | HTTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL1744968 | 0.79 | HTT (0.66) | HTTKMT2APOLBALDH1A1MAPT | |
| SCHEMBL11832224 | 0.79 | HTT (0.65) | HTTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL4703901 | 0.78 | KMT2A (0.55) | HTTKMT2AMEN1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| EP-2619185-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038942-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP12, MMP10 | HTT 4338/4885KMT2A 3501/4885MEN1 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.